LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 110 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q1 2022. The put-call ratio across all filers is 0.38 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $17,110 | -70.5% | 14,500 | -64.8% | 0.00% | – |
Q2 2023 | $58,065 | -95.3% | 41,181 | -95.0% | 0.00% | – |
Q1 2023 | $1,224,581 | +502.8% | 816,387 | +370.2% | 0.00% | – |
Q4 2022 | $203,134 | +120.8% | 173,619 | +113.8% | 0.00% | – |
Q3 2022 | $92,000 | -66.2% | 81,200 | -52.9% | 0.00% | – |
Q2 2022 | $272,000 | -13.4% | 172,400 | -15.7% | 0.00% | – |
Q1 2022 | $314,000 | -87.1% | 204,400 | -79.5% | 0.00% | – |
Q4 2021 | $2,442,000 | +33.7% | 996,860 | +37.6% | 0.00% | – |
Q3 2021 | $1,826,000 | +114.1% | 724,501 | +142.0% | 0.00% | – |
Q2 2021 | $853,000 | -68.0% | 299,319 | -73.6% | 0.00% | – |
Q1 2021 | $2,665,000 | +24.6% | 1,134,482 | -6.6% | 0.00% | – |
Q4 2020 | $2,138,000 | +4759.1% | 1,214,286 | +2494.6% | 0.00% | – |
Q3 2020 | $44,000 | +25.7% | 46,800 | +15.8% | 0.00% | – |
Q2 2020 | $35,000 | -56.2% | 40,400 | -58.1% | 0.00% | – |
Q1 2020 | $80,000 | +50.9% | 96,381 | +62.6% | 0.00% | – |
Q4 2019 | $53,000 | -44.2% | 59,291 | -39.4% | 0.00% | – |
Q3 2019 | $95,000 | – | 97,820 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
BROADWOOD CAPITAL INC | 34,005,379 | $83,313,000 | 5.12% |
Defender Capital, LLC. | 4,997,870 | $12,245,000 | 3.92% |
Raffles Associates | 543,590 | $1,332,000 | 1.28% |
Prescott General Partners LLC | 1,851,851 | $4,537,000 | 0.16% |
DCF Advisers, LLC | 85,000 | $208,000 | 0.08% |
Long Focus Capital Management, LLC | 215,000 | $527,000 | 0.07% |
Beirne Wealth Consulting Services, LLC | 45,000 | $110,000 | 0.06% |
DAFNA Capital Management LLC | 80,000 | $196,000 | 0.05% |
Strategic Wealth Investment Group, LLC | 65,069 | $159,000 | 0.04% |
Fort Sheridan Advisors LLC | 52,931 | $130,000 | 0.04% |